William Blair Downgrades Sequenom (SQNM) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
Go back to William Blair Downgrades Sequenom (SQNM) to Market Perform
July 25, 2013 9:43 AM EDT
Wedbush today maintained an Outperform rating on Sequenom (NASDAQ: SQNM) with a price target of $5.00. Shares tumbled as a result of disappointing earnings on Wednesday. Along with many other companies in the diagnostics industry, Sequenom experienced delays in receipt of payments as a result of... More
July 25, 2013 8:24 AM EDT
Ladenburg Thalmann downgraded Sequenom (NASDAQ: SQNM) from Buy to Neutral.
For an analyst ratings summary and ratings history on Sequenom click here. For more ratings news on Sequenom click here.
Shares of Sequenom closed at $4.69 yesterday, with a 52 week range of $2.65-$5.36.... More
July 25, 2013 7:16 AM EDT
Lazard Capital downgraded Sequenom (NASDAQ: SQNM) from Buy to Neutral.
For an analyst ratings summary and ratings history on Sequenom click here. For more ratings news on Sequenom click here.
Shares of Sequenom closed at $4.69 yesterday, with a 52 week range of $2.65-$5.36.... More
July 24, 2013 4:08 PM EDT
Sequenom, Inc. (NASDAQ: SQNM) reported Q2 EPS of ($0.27), $0.05 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $24.5 million versus the consensus estimate of $46.25 million.
Operations Update
The annualized run rate for the MaterniT21 PLUS test at the end of the second quarter surpassed 150,000 samples.
"We have managed through challenges associated with the tremendous growth in our business following the launch of MaterniT21 PLUS. Uncertainties associated with the newly introduced coding changes in the molecular... More
